SciSparc SPRC
NASDAQ SPRC
$6.70 -0.04 (-0.67%)
As of: Aug 21, 2026 · 3:59 PM EDT

SciSparc (SPRC) Net Income towards Common Stockholders (2016 - 2022)

SciSparc (SPRC) posted Net Income towards Common Stockholders of -$359000.0 for Q4 2022, down 113.14% sequentially from $2.7 million in Q3 2022.

SciSparc (SPRC) Net Income towards Common Stockholders (2016 - 2022) Analysis & Trends

SciSparc has reported Net Income towards Common Stockholders for 5 years, with the latest figure at -$359000.0 in Q4 2022.

  • Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$359000.0 in Q4 2022, while the trailing twelve-month figure through Jun 2024 was -$359000.0 (down 115.13% YoY) and the FY2025 annual result came in at -$12.2 million, down 93.81% from the prior year.
  • Net Income towards Common Stockholders slipped to -$359000.0 in Q4 2022 per SPRC's latest filing, from $2.7 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $2.7 million in Q3 2022 and troughed at -$12.3 million in Q4 2018.
  • A 3-year average of -$438250.0 and a median of $1.2 million in 2018 frame the typical range for Net Income towards Common Stockholders.
  • The widest YoY moves for Net Income towards Common Stockholders: up 222.01% in 2018, down 554.79% in 2018.
  • Over 3 years, Net Income towards Common Stockholders stood at -$12.3 million in 2018, then surged by 101.6% to $197000.0 in 2019, then plunged by 282.23% to -$359000.0 in 2022.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$359000.0, $2.7 million, and $197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 SciSparc 831,418.60 831,418.60 - -

Historic Data

Download Data
DateValue
Dec 31, 2022 -359,000.00
Sep 30, 2022 2.73 Mn
Jun 30, 2019 197,000.00
Mar 31, 2019 1.85 Mn
Dec 31, 2018 -12.33 Mn
Sep 30, 2018 1.14 Mn
Jun 30, 2018 1.21 Mn
Mar 31, 2018 2.05 Mn
Dec 31, 2017 2.71 Mn
Sep 30, 2017 1.03 Mn
Jun 30, 2017 1.86 Mn
Mar 31, 2017 636,000.00
Dec 31, 2016 429,000.00
Sep 30, 2016 536,000.00
Jun 30, 2016 533,000.00